OncoMatch/Clinical Trials/NCT06598306
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Is NCT06598306 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Tarlatamab for extensive stage small cell lung cancer.
Treatment: Tarlatamab — The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
ES-SCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — SCLC
progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC
Cannot have received: DLL3 targeted therapy
Participants that have received prior DLL3 targeted therapy
Lab requirements
Kidney function
adequate organ function (cardiac, pulmonary, kidney, and liver)
Liver function
adequate organ function (cardiac, pulmonary, kidney, and liver)
Cardiac function
adequate organ function (cardiac, pulmonary, kidney, and liver)
Participants must have adequate organ function (cardiac, pulmonary, kidney, and liver)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California, Norris Comprehensive Cancer Center · Los Angeles, California
- University of Illinois Chicago · Chicago, Illinois
- Trinity Health Saint Joseph Mercy Ann Arbor · Ann Arbor, Michigan
- Avera Cancer Institute · Sioux Falls, South Dakota
- University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06598306 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior DLL3 targeted therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages